Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorCentre Henri Becquerel

About this trial

The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.

Eligibility criteria

Qualifiers

Signed informed consent

Patient with histologically proven TNBC

Indication for neo-adjuvant chemo-immunotherapy treatment

Age between 18 and 75

Disqualifiers

Pregnant or breast-feeding women

Contraindication to immunotherapy

Inflammatory breast cancer (T4d)

Metastatic patients

Trial design

Treatments tested in this trial

  • Imaging assessment

Treatment groups

115 Participants
are divided into 1 treatment group

Sponsors and collaborators